Related Experiment Video
Updated: Jul 10, 2026
13:19
Enhanced Oil Recovery using a Combination of Biosurfactants
Published on: June 3, 2022
Pulmonary surfactant: emerging protein analogues
J Johansson1, M Gustafsson, M Palmblad
1Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden. jan.johansson@mbb.ki.se
Summary
Developing synthetic peptide/lipid surfactants offers a promising alternative to animal-derived treatments for respiratory distress syndrome (RDS). Further research into surfactant protein B (SP-B) and C (SP-C) analogues is crucial for enhancing efficacy.
Area of Science:
- Biochemistry
- Pulmonary Medicine
- Biomaterials Science
Background:
- Current surfactant therapies for respiratory distress syndrome (RDS) rely on animal-derived lung extracts.
- These preparations contain phospholipids and hydrophobic proteins (SP-B, SP-C).
- Limitations exist in current purification methods and scalability for broader applications.
Purpose of the Study:
- To explore the development of synthetic peptide/lipid surfactants as alternatives to animal-derived sources.
- To investigate the potential of designing analogues of SP-B and SP-C proteins.
- To address challenges in producing sufficient quantities for evaluating surfactant therapy in various respiratory diseases.
Main Methods:
- Design and synthesis of surfactant protein C (SP-C) analogues.
- Evaluation of SP-C analogues' ability to accelerate lipid spreading.
- Assessment of physiological activity in animal models of RDS.
- In vitro and in vivo testing of surfactant preparations containing SP-B analogues.
Main Results:
- SP-C analogues demonstrated effectiveness in accelerating lipid spreading and showed physiological activity in RDS animal models.
- However, in vivo activity of SP-C analogue-based surfactants was inferior to natural sources.
- This suggests potential roles for palmitoylation and the presence of SP-B in full surfactant activity.
- Surfactant preparations with SP-B analogues showed promising in vitro and in vivo results.
Conclusions:
- Synthetic peptide/lipid surfactants are a viable avenue, but current analogues require optimization.
- Further investigation into SP-B analogues and combinations of SP-B/SP-C analogues is essential.
- Addressing limitations like palmitoylation and the synergistic role of SP-B may improve synthetic surfactant efficacy.
Related Concept Videos
01:05Breathing
The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
01:27Surface Active Agents
Surfactants, named for their behavior at interfaces, positively adsorb at the interfaces of two phases, reducing interfacial tension. Their versatility as emulsifiers, detergents, and foaming agents stems from this ability. Surfactants, often termed amphiphiles, share the property of amphipathy, with molecules having both hydrophilic and hydrophobic portions. The hydrophilic part is called the head, and the hydrophobic part, including an elongated alkyl substituent, forms the tail.Surfactants...
01:30Micelles
Micelle formation is an intricate process that hinges on the properties of amphiphilic or amphipathic molecules and the conditions of the system in which they are found. Amphiphilic molecules, which have both hydrophilic (water-attracting) and hydrophobic (water-repelling) parts, play a critical role in this process.In aqueous environments, these molecules arrange themselves such that their hydrophilic heads are turned towards the water phase, while their hydrophobic tails are oriented away...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...